Left untreated, human immunodeficiency virus (HIV) replicates at a rapid
rate, with the eventual production of billions of new virus particles per
day. Given the propensity of HIV to mutate, the possibility exists that each
newly produced virus contains at least 1 new mutation. Thus, from a darwinian
perspective, ongoing viral replication in the presence of therapy should result
in the rapid selection of drug resistance mutations and subsequent virologic
rebound. These basic principles have provided the theoretical context for
the "hit hard" therapeutic approach to HIV disease.1
According to current treatment guidelines,1- 3
complete viral suppression should be the goal of therapy. Once therapy is
initiated, plasma viremia, as measured by the concentration of viral RNA in
plasma, should decrease to below the level of detection using the most sensitive
assay available.2,3 Persistent
viremia suggests ongoing viral replication and treatment failure. The findings
from 2 articles in this issue of THE JOURNAL raise questions about this conceptual
framework, and based on data from the 2 studies, it may be argued that "complete"
viral suppression may not be a prerequisite for durable treatment benefit.
* * SCHEDULED MAINTENANCE * *
Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 32
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...
The Rational Clinical Examination
Evidence Summary and Review 3
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.